PRQR – ProQR Therapeutics N.V.
ProQR Therapeutics N.V.PRQR
$1.14Name : ProQR Therapeutics N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $119,942,816.00
EPSttm : -0.36
ProQR Therapeutics N.V.
$1.14
0.00%$0.0000Float Short %
1.19
Margin Of Safety %
Put/Call OI Ratio
0.3
EPS Next Q Diff
-0.07
EPS Last/This Y
-0.32
EPS This/Next Y
0.67
Price
1.14
Target Price
10.68
Analyst Recom
1
Performance Q
-50.43
Relative Volume
0.92
Beta
0.46
Ticker: PRQR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-20 | PRQR | 1.7 | 0.12 | 0.00 | 2841 |
| 2025-03-21 | PRQR | 1.645 | 0.12 | 0.00 | 2861 |
| 2025-03-24 | PRQR | 1.65 | 0.37 | 0.00 | 1144 |
| 2025-03-25 | PRQR | 1.61 | 0.37 | 0.00 | 1144 |
| 2025-03-26 | PRQR | 1.53 | 0.37 | 0.00 | 1144 |
| 2025-03-27 | PRQR | 1.44 | 0.37 | 0.00 | 1144 |
| 2025-03-28 | PRQR | 1.4 | 0.37 | 0.00 | 1144 |
| 2025-03-31 | PRQR | 1.34 | 0.31 | 999.99 | 1099 |
| 2025-04-01 | PRQR | 1.29 | 0.31 | 999.99 | 1099 |
| 2025-04-02 | PRQR | 1.37 | 0.31 | 999.99 | 1099 |
| 2025-04-03 | PRQR | 1.27 | 0.32 | 0.00 | 1109 |
| 2025-04-04 | PRQR | 1.185 | 0.32 | 0.67 | 1122 |
| 2025-04-07 | PRQR | 1.185 | 0.31 | 0.71 | 1122 |
| 2025-04-08 | PRQR | 1.13 | 0.31 | 1.50 | 1126 |
| 2025-04-09 | PRQR | 1.2 | 0.31 | 1.50 | 1126 |
| 2025-04-10 | PRQR | 1.135 | 0.31 | 1.20 | 1137 |
| 2025-04-11 | PRQR | 1.11 | 0.30 | 0.00 | 1147 |
| 2025-04-14 | PRQR | 1.18 | 0.30 | 0.00 | 1147 |
| 2025-04-15 | PRQR | 1.19 | 0.30 | 0.00 | 1167 |
| 2025-04-16 | PRQR | 1.14 | 0.30 | 999.99 | 1167 |
| 2025-04-17 | PRQR | 1.15 | 0.30 | 999.99 | 1167 |
| 2025-04-18 | PRQR | 1.14 | 0.30 | 999.99 | 1167 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-20 | PRQR | 1.63 | -59.7 | - | -0.67 |
| 2025-03-21 | PRQR | 1.64 | -59.7 | - | -0.67 |
| 2025-03-24 | PRQR | 1.65 | -59.7 | - | -0.67 |
| 2025-03-25 | PRQR | 1.61 | -59.7 | - | -0.67 |
| 2025-03-26 | PRQR | 1.52 | -59.7 | - | -0.67 |
| 2025-03-27 | PRQR | 1.44 | -59.7 | - | -0.67 |
| 2025-03-28 | PRQR | 1.40 | -59.7 | - | -0.67 |
| 2025-03-31 | PRQR | 1.33 | -59.7 | - | -0.67 |
| 2025-04-01 | PRQR | 1.29 | -59.7 | - | -0.67 |
| 2025-04-02 | PRQR | 1.37 | -59.7 | - | -0.67 |
| 2025-04-03 | PRQR | 1.27 | -59.7 | - | -0.67 |
| 2025-04-04 | PRQR | 1.18 | -59.7 | - | -0.67 |
| 2025-04-07 | PRQR | 1.18 | -59.7 | - | -0.67 |
| 2025-04-08 | PRQR | 1.13 | -59.7 | - | -0.67 |
| 2025-04-09 | PRQR | 1.21 | -59.7 | - | -0.67 |
| 2025-04-10 | PRQR | 1.13 | -59.7 | - | -0.67 |
| 2025-04-11 | PRQR | 1.11 | -59.7 | - | -0.67 |
| 2025-04-14 | PRQR | 1.18 | -59.7 | - | -0.67 |
| 2025-04-15 | PRQR | 1.19 | -59.7 | - | -0.67 |
| 2025-04-16 | PRQR | 1.15 | -59.7 | - | -0.67 |
| 2025-04-17 | PRQR | 1.14 | -59.7 | - | -0.67 |
| 2025-04-18 | PRQR | 1.14 | -59.7 | - | -0.67 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-20 | PRQR | 0.00 | 31.14 | 1.28 |
| 2025-03-21 | PRQR | 0.00 | 31.14 | 1.28 |
| 2025-03-24 | PRQR | 0.00 | 31.14 | 1.28 |
| 2025-03-25 | PRQR | 0.00 | 31.14 | 1.28 |
| 2025-03-26 | PRQR | 0.00 | 31.14 | 1.45 |
| 2025-03-27 | PRQR | 0.00 | 31.14 | 1.45 |
| 2025-03-28 | PRQR | 0.00 | 31.14 | 1.45 |
| 2025-03-31 | PRQR | 0.00 | 31.14 | 1.45 |
| 2025-04-01 | PRQR | 0.00 | 31.14 | 1.45 |
| 2025-04-02 | PRQR | 0.00 | 31.14 | 1.45 |
| 2025-04-03 | PRQR | 0.00 | 31.14 | 1.45 |
| 2025-04-04 | PRQR | 0.00 | 31.14 | 1.45 |
| 2025-04-07 | PRQR | 0.00 | 31.14 | 1.45 |
| 2025-04-08 | PRQR | 0.00 | 31.14 | 1.45 |
| 2025-04-09 | PRQR | 0.00 | 31.14 | 1.45 |
| 2025-04-10 | PRQR | 0.00 | 31.14 | 1.19 |
| 2025-04-11 | PRQR | 0.00 | 31.14 | 1.19 |
| 2025-04-14 | PRQR | 0.00 | 31.14 | 1.19 |
| 2025-04-15 | PRQR | 0.00 | 31.14 | 1.19 |
| 2025-04-16 | PRQR | 0.00 | 31.14 | 1.19 |
| 2025-04-17 | PRQR | 0.00 | 31.14 | 1.19 |
| 2025-04-18 | PRQR | 0.00 | 31.14 | 1.19 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.1
Avg. EPS Est. Current Quarter
-0.16
Avg. EPS Est. Next Quarter
-0.17
Insider Transactions
Institutional Transactions
31.14
Beta
0.46
Average Sales Estimate Current Quarter
4
Average Sales Estimate Next Quarter
4
Fair Value
Quality Score
29
Growth Score
30
Sentiment Score
76
Actual DrawDown %
88
Max Drawdown 5-Year %
-93.9
Target Price
10.68
P/E
Forward P/E
PEG
P/S
5.87
P/B
1.28
P/Free Cash Flow
EPS
-0.35
Average EPS Est. Cur. Y
-0.67
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-147.03
Relative Volume
0.92
Return on Equity vs Sector %
-51.3
Return on Equity vs Industry %
-37.9
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.12
EBIT Estimation
ProQR Therapeutics N.V.Sector: Healthcare
Industry: Biotechnology
Employees: 166
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
stock quote shares PRQR – ProQR Therapeutics N.V. Stock Price stock today
news today PRQR – ProQR Therapeutics N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch PRQR – ProQR Therapeutics N.V. yahoo finance google finance
stock history PRQR – ProQR Therapeutics N.V. invest stock market
stock prices PRQR premarket after hours
ticker PRQR fair value insiders trading